Landos Biopharma’s lead asset, BT-11, is a first-in-class, oral, gut-restricted small molecule that targets the LANCL2 pathway for treatment of inflammatory bowel disease. The company completed Phase 1 clinical testing (results published May 2019) that showed BT-11 was well-tolerated and produced lower fecal calprotectin levels versus placebo across treated groups. Landos initiated Phase 2 clinical testing of BT-11 in 2019 and plans global Phase 2 trials in ulcerative colitis and Crohn’s disease. The company reports a broader pipeline of oral compounds for other autoimmune diseases, several of which it anticipates advancing to IND and Phase 1 testing in 2020. The recently completed financing is intended to support advancement of BT-11 into global Phase 2 studies. Landos is headquartered in Blacksburg, VA. Landos Biopharma focuses on discovery and development of first-in-class oral therapeutics for autoimmune diseases, with a lead clinical asset, BT-11, targeting Crohn’s disease and ulcerative colitis. The company advances a novel target pathway, LANCL2, which exerts potent anti-inflammatory effects and underpins BT-11’s mechanism of action. BT-11 is described as a locally acting, orally active small molecule that has shown a benign safety profile in animal models and is advancing toward an IND filing. Landos says its pipeline includes additional compounds for other autoimmune indications and aims to address limitations of current therapies that have limited efficacy and significant side effects. The company partners operationally with Xontogeny, LLC for management support and strategic direction, and is led by founder and CEO Dr. Josep Bassaganya-Riera. Landos is headquartered in Blacksburg, VA and positions its work against a large autoimmune market and a multibillion-dollar IBD therapeutics opportunity.

Total raised

$70M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2019